Cipla Embraces Gilead and a New Era as Priorities Change Divya Rajagopal Mumbai:   Once a steadfast backer of generics, co now enters into a deal to make Hepatitis drug for MNC ruary last year Hamied had said  In an interview to ET in 2013, YK Hamied, the founder chairm an of Cipla, and some say the scourge of multinational drug companies, prophesied that the Indian drug industry will witness a sea change around the year 2020.“The momentum of 1972 to 1995 (pre-patent era) can't stop . It will last till 2015, but not after that. So to protect myself for 2020 I have to make radical changes.“ On Monday , the world got a glimpse of the kind of change that Hamied had in mind when Cipla teamed up with California-based Gilead Lifesciences to make and sell its path-breaking Hepatitis C drug Sofosbuvir under voluntary licence. On the face of it, there is nothing wrong with this kind of a deal.Pharma companies ink many such pacts on a regular basis. But what...